What is King Pharmaceuticals's favorable PPD?

King Pharmaceuticals (KG) reported favorable PPD of -$6.62M in Q3 2025.

King Pharmaceuticals KG Favorable PPD

Discontinued — last reported Q3 '25

Segments

By product

See full

International$824K—

AmTrust Quota Share-$370K—

GLS$262K—

LPT/ADC Agreement-$179K—

European Hospital Liability Quota Share-$2K—

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept kg:LiabilityforUnpaidClaimsandClaimsAdjustmentExpensePeriodIncreaseDecreaseNetofCommissionChanges.

The official record: King Pharmaceuticals’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's favorable ppd.

Connect your AI assistant and break it down by segment, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's favorable PPD?: King Pharmaceuticals (KG) reported favorable PPD of -$6.62M in Q3 2025.